5 articles
FMC and Corteva signed a deal expanding access to FMC's rimisoxafen herbicide technology across the Americas, with Corteva paying $200 million for active ingredient supply to manage resistant weeds in
Five new M&A transactions were announced for the week ended May 11, matching prior volumes. A notable deal involves FMC agreeing to sell a business unit, though YTD values remain behind 2025 levels.
FMC is exploring strategic options, including a potential sale, following an 18% revenue drop and net loss due to price declines and patent expirations. Facing credit downgrades, the company plans to
FMC reported a net loss due to goodwill impairment and expects lower sales in 2026 amid declining pricing.
FMC Corporation is conducting a strategic review that may involve asset sales to reduce its debt burden by $1 billion. This financial restructuring aims to strengthen the company's balance sheet.
ChemBrief